Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.60 |
| ▸ | KLK7 | P49862 | 11/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 9/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18589299 | 1.00 | BCHE (0.60) | BCHEKLK7KLK5PDE4DSLC6A2 | |
| SCHEMBL18557872 | 1.00 | BCHE (0.60) | BCHEKLK7KLK5PDE4DSLC6A2 | |
| SCHEMBL2399000 | 1.00 | BCHE (0.60) | BCHEKLK7KLK5PDE4DSLC6A2 | |
| SCHEMBL21258139 | 1.00 | BCHE (0.60) | BCHEKLK7KLK5PDE4DSLC6A2 | |
| SCHEMBL12258542 | 1.00 | BCHE (0.60) | BCHEKLK7KLK5PDE4DSLC6A2 | |
| SCHEMBL12902908 | 1.00 | BCHE (0.60) | BCHEKLK7KLK5PDE4DSLC6A2 | |
| SCHEMBL16403009 | 1.00 | BCHE (0.60) | BCHEKLK7KLK5PDE4DSLC6A2 | |
| SCHEMBL21574397 | 0.90 | BCHE (0.65) | BCHEKLK7KLK5 | |
| SCHEMBL4752349 | 0.90 | BCHE (0.65) | BCHEKLK7KLK5 | |
| SCHEMBL17104807 | 0.87 | BCHE (0.52) | BCHEKLK7KLK5PDE4DSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4204441-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022046739-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SENDA BIOSCIENCES INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3891751-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020118238-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-10364251-B2 | Polyesters from assymetrical monomers based upon bisanhydrohexitols | NEW JERSEY INSTITUTE OF TECHNOLOGY (US) | 2019-07-30 | — | — | US | disclosed |
| US-20170210750-A1 | Polyesters From Assymetrical Monomers Based Upon Bisanhydrohexitols | NEW JERSEY INSTITUTE OF TECHNOLOGY | 2017-07-27 | — | — | US | disclosed |
| US-9580544-B2 | Polyesters from asymetrical monomers based upon bisanhydrohexitols | NEW JERSEY INSTITUTE OF TECHNOLOGY (US) | 2017-02-28 | — | — | US | disclosed |
| CN-102947360-B | New polyester from asymmetry monomers based on double anhydrohexitols | 新泽西理工学院 | 2016-12-21 | — | — | CN | disclosed |
| EP-2547708-A2 | NEW POLYESTERS FROM ASYMMETRICAL MONOMERS BASED UPON BISANHYDROHEXITOLS | New Jersey Institute of Technology (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20110237757-A1 | Polyesters From Assymetrical Monomers Based Upon Bisanhydrohexitols | IOWA CORN PROMOTION BOARD (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011116275-A2 | NEW POLYESTERS FROM ASYMMETRICAL MONOMERS BASED UPON BISANHYDROHEXITOLS | NEW JERSEY INSTITUTE OF TECHNOLOGY (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SLC10A2, SLC10A1, BCAT2 | BCHE 183/4885KLK7 2983/4885KLK5 1496/4885 |
| US-10364251-B2 | Polyesters from assymetrical monomers based upon bisanhydrohexitols | ACMSD, AKR1C2, ALDOA | BCHE 2426/4885KLK7 2583/4885KLK5 4060/4885 |
| US-20110237757-A1 | Polyesters From Assymetrical Monomers Based Upon Bisanhydrohexitols | ADSL, FHIT, ADSS2 | BCHE 1980/4885KLK7 2547/4885KLK5 3757/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | BCHE 3475/4885KLK7 1726/4885KLK5 4124/4885 |
| US-20170210750-A1 | Polyesters From Assymetrical Monomers Based Upon Bisanhydrohexitols | ADSL, FHIT, ADSS2 | BCHE 1980/4885KLK7 2547/4885KLK5 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.